Newer steroid-sparing therapies, such as IL-6 inhibitors and selective JAK1 inhibitors like upadacitinib (Rinvoq), have shown promise in improving remission rates while reducing adverse effects.
Read More
A collection of videos, study abstracts, and other resources all focused on giant cell arteritis.
Read More
The following is a summary of “Population-Based Performance of Inflammatory Markers in Giant Cell...
Read More
The following is a summary of “Optic nerve sheath enhancement on orbital MRI in giant cell...
Read More
In the SELECT-GCA trial, upadacitinib was found to be superior in comparison to a placebo in patients with giant cell arteritis.
Read More
Upadacitinib 15 mg demonstrated convincing results as a treatment for giant cell arteritis in the phase 3 SELECT-GCA trial.
Read More
